Nurix Therapeutics, Inc.
NRIX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001549595
In the last 90 days, Nurix Therapeutics, Inc. insiders filed 0 open-market purchases and 10 sales; 211 institutions reported holding it in 13F filings for Q2 2026, worth $2.84B in total; ARK Invest is the only superinvestor holding it.
13F holders, Q1 2022
Institutional positions in Nurix Therapeutics, Inc. as of Mar 31, 2022. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 117
- −8 vs. Q4 2021
- Shares held
- 40.4M
- −47.1K (−0.1%) vs. Q4 2021
- Total value
- $565.6M
- −$604.5M (−51.7%) vs. Q4 2021
- New holders
- 17
- 50 more added
- Sold out
- 25
- 32 more reduced
Compare with Q4 2021: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting NRIX on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 211 | $2.84B |
| Q1 2026 | 196 | $1.81B |
| Q4 2025 | 182 | $2.15B |
| Q3 2025 | 173 | $783.3M |
| Q2 2025 | 164 | $1.01B |
| Q1 2025 | 170 | $1.01B |
| Q4 2024 | 175 | $1.53B |
| Q3 2024 | 172 | $1.53B |
| Q2 2024 | 174 | $1.36B |
| Q1 2024 | 139 | $721.3M |
| Q4 2023 | 131 | $475.6M |
| Q3 2023 | 129 | $352.5M |
| Q2 2023 | 126 | $435.7M |
| Q1 2023 | 124 | $376.6M |
| Q4 2022 | 119 | $468.6M |
| Q3 2022 | 118 | $561.0M |
| Q2 2022 | 106 | $568.4M |
| Q1 2022 | 117 | $565.6M |
| Q4 2021 | 125 | $1.17B |
| Q3 2021 | 113 | $1.18B |
| Q2 2021 | 104 | $1.05B |
| Q1 2021 | 101 | $1.29B |
Institutions, Q1 2022
Shares, value and share of portfolio for each institution holding Nurix Therapeutics, Inc.; share changes are against Q4 2021.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Candriam Luxembourg S.C.A. | 765,106 | $10.7M | 0.07% | −28,997−3.7% | Reduced |
| Wellington Management Group LLP | 842,373 | $11.8M | 0.00% | −319,943−27.5% | Reduced |
| Soleus Capital Management, L.P. | 1,011,638 | $14.2M | 2.19% | +268,400+36.1% | Added |
| Foresite Capital Management IV, LLC | 1,030,798 | $14.4M | 4.04% | −175,000−14.5% | Reduced |
| FMR LLC | 1,122,023 | $15.7M | 0.00% | +13,920+1.3% | Added |
| Boxer Capital, LLC | 1,224,892 | $17.2M | 0.88% | 00.0% | Unchanged |
| Bain Capital Life Sciences Investors, LLC | 1,284,313 | $18.0M | 1.75% | 00.0% | Unchanged |
| Pictet Asset Management SA | 1,439,282 | $20.2M | 0.02% | +317,347+28.3% | Added |
| Wasatch Advisors Inc | 1,546,689 | $21.7M | 0.11% | +343,100+28.5% | Added |
| Eventide Asset Management, LLC | 1,870,000 | $26.2M | 0.41% | 00.0% | Unchanged |
| TRV GP III, LLC | 1,922,549 | $26.9M | 7.31% | −500,000−20.6% | Reduced |
| Vanguard Group Inc | 2,028,063 | $28.4M | 0.00% | +37,499+1.9% | Added |
| State Street Corp | 2,302,544 | $32.3M | 0.00% | +744,832+47.8% | Added |
| Baker Bros. Advisors LP | 2,454,082 | $34.4M | 0.20% | 00.0% | Unchanged |
| BlackRock Inc. | 2,524,643 | $35.4M | 0.00% | −23,218−0.9% | Reduced |
| Redmile Group, LLC | 3,018,784 | $42.3M | 1.32% | +60,500+2.0% | Added |
| Price T Rowe Associates Inc | 4,806,289 | $67.3M | 0.01% | −64,795−1.3% | Reduced |
| Clough Capital Partners L P | 0 | $0 | 0.00% | −473,048−100.0% | Sold out |
| Rock Springs Capital Management LP | 0 | $0 | 0.00% | −321,050−100.0% | Sold out |
| OrbiMed Advisors LLC | 0 | $0 | 0.00% | −184,468−100.0% | Sold out |
| Endurant Capital Management LP | 0 | $0 | 0.00% | −43,542−100.0% | Sold out |
| Prudential Financial Inc | 0 | $0 | 0.00% | −41,495−100.0% | Sold out |
| Jefferies Group LLC | 0 | $0 | 0.00% | −41,800−100.0% | Sold out |
| HighVista Strategies LLC | 0 | $0 | 0.00% | −18,796−100.0% | Sold out |
| SG Americas Securities, LLC | 0 | $0 | 0.00% | −14,599−100.0% | Sold out |
| Algert Global LLC | 0 | $0 | 0.00% | −13,053−100.0% | Sold out |
| Winton Group Ltd | 0 | $0 | 0.00% | −11,509−100.0% | Sold out |
| Parametric Portfolio Associates LLC | 0 | $0 | 0.00% | −9,847−100.0% | Sold out |
| AlphaCrest Capital Management LLC | 0 | $0 | 0.00% | −9,842−100.0% | Sold out |
| Marshall Wace, LLP | 0 | $0 | 0.00% | −9,202−100.0% | Sold out |
| Guggenheim Capital LLC | 0 | $0 | 0.00% | −8,630−100.0% | Sold out |
| EP Wealth Advisors, LLC | 0 | $0 | 0.00% | −8,333−100.0% | Sold out |
| State Board of Administration of Florida Retirement System | 0 | $0 | 0.00% | −8,031−100.0% | Sold out |
| Natixis | 0 | $0 | 0.00% | −7,970−100.0% | Sold out |
| Handelsbanken Fonder AB | 0 | $0 | 0.00% | −7,600−100.0% | Sold out |
| Schonfeld Strategic Advisors LLC | 0 | $0 | 0.00% | −7,600−100.0% | Sold out |
| American Financial Group Inc | 0 | $0 | 0.00% | −7,442−100.0% | Sold out |
| Dynamic Technology Lab Private Ltd | 0 | $0 | 0.00% | −7,173−100.0% | Sold out |
| Amundi | 0 | $0 | 0.00% | −5,113−100.0% | Sold out |
| Migdal Insurance & Financial Holdings Ltd. | 0 | $0 | 0.00% | −371−100.0% | Sold out |
| High Net Worth Advisory Group LLC | 0 | $0 | 0.00% | −300−100.0% | Sold out |
| Parallel Advisors, LLC | 0 | $0 | 0.00% | −9−100.0% | Sold out |